Table 1.
Baseline Characteristics and Surgical and Pathologic Factors of 876 Patients With NSCLC Who Underwent Complete Resection
| Characteristics | Number of Patients (%) | |||||
|---|---|---|---|---|---|---|
| Sex | ||||||
| Male | 491 (56.1) | |||||
| Female | 385 (43.9) | |||||
| Age (y) | Median: 79 | Range: 75–92 | Q1–Q3: 77–82 | |||
| Clinical stage (UICC-TNM eighth classification) | ||||||
| 0 | 29 (3.3) | |||||
| IA1 | 131 (15.0) | |||||
| IA2 | 254 (29.0) | |||||
| IA3 | 158 (18.0) | |||||
| IB | 134 (15.3) | |||||
| IIA | 36 (4.1) | |||||
| IIB | 96 (11.0) | |||||
| IIIA | 35 (4.0) | |||||
| IIIB | 3 (0.3) | |||||
| ECOG Performance status | ||||||
| 0 | 717 (81.8) | |||||
| 1 | 152 (17.4) | |||||
| 2 | 5 (0.6) | |||||
| 3 | 1 (0.1) | |||||
| 4 | 1 (0.1) | |||||
| Smoking history | ||||||
| Never | 363 (41.4) | |||||
| Ever | 513 (58.6) | |||||
| Smoking years | Median: 43 | Range: 0–66 | Q1–Q3: 30–54 | |||
| Number of daily cigarettes | Median: 20 | Range: 0–80 | Q1–Q3: 15–30 | |||
| Emphysema | ||||||
| No | 623 (71.1) | |||||
| Yes | 253 (28.9) | |||||
| Interstitial pneumonia | ||||||
| No | 788 (90.0) | |||||
| Yes | 88 (10.0) | |||||
| Number of medications | ||||||
| 0 | 63 (7.2) | |||||
| 1-3 | 255 (29.1) | |||||
| 4-9 | 464 (53.0) | |||||
| ≥ 10 | 94 (10.7) | |||||
| Operation | ||||||
| Wedge Resection | 95 (10.8) | |||||
| Segmentectomy | 133 (15.2) | |||||
| Lobectomy | 639 (72.9) | |||||
| Bilobectomy | 6 (0.7) | |||||
| Pneumonectomy | 3 (0.3) | |||||
| Lymph node dissection | ||||||
| ND0–1 | 371 (42.4) | |||||
| ND2a or more | 505 (57.6) | |||||
| Combined resection | ||||||
| No | 863 (98.5) | |||||
| Yes | 13 (1.5) | |||||
| Operation time (min) | Median: 157 | Range: 33–524 | Q1–Q3: 119–205 | |||
| Histology | ||||||
| Adenocarcinoma | 678 (77.4) | |||||
| Squamous cell carcinoma | 169 (19.3) | |||||
| Large cell carcinoma | 1 (0.1) | |||||
| Adenosquamous carcinoma | 16 (1.8) | |||||
| Others | 12 (1.4) | |||||
| Pathologic stage (UICC-TNM Eighth classification) | ||||||
| 0 | 31 (3.5) | |||||
| IA1 | 171 (19.5) | |||||
| IA2 | 207 (23.6) | |||||
| IA3 | 114 (13.0) | |||||
| IB | 127 (14.5) | |||||
| IIA | 45 (5.1) | |||||
| IIB | 96 (11.0) | |||||
| IIIA | 74 (8.4) | |||||
| IIIB | 11 (1.3) | |||||
| Postoperative chemotherapy | ||||||
| None | 837 (95.5) | |||||
| Tegafur-uracil | 30 (3.4) | |||||
| Platinum-based | 8 (0.9) | |||||
| Missing | 1 (0.1) | |||||
| Postoperative radiotherapy | ||||||
| None | 874 (99.8) | |||||
| Yes | 1 (0.1) | |||||
| Missing | 1 (0.1) | |||||
| G8 score at enrollment | Mean: 14.0 | Median: 14 | SD: 1.8 | Range: 6.5–17 | ||
| CCI score | Mean: 0.9 | Median: 0 | SD: 1.2 | Range: 0–8 | ||
| Baseline TMIG-IADL score | Mean: 11.6 | Median: 12 | SD: 1.8 | Range: 2–13 | Q1–Q3: 11–13 |
CCI, Charlson comorbidity index; ECOG, Eastern Cooperative Oncology Group; G8, geriatric screening tool; ND0, no node dissection; ND1, hilar node dissection; ND2, mediastinal node dissection; TMIG-IADL, Tokyo Metropolitan Institute of Gerontology Index of Competence Instrumental Activities of Daily Living; Q1, first quartile; Q3, third quartile; UICC, Union for International Cancer Control.